MELBOURNE, Australia and INDIANAPOLIS, June 25, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that its Telix Manufacturing Solutions (TMS) facility in Brussels South (Seneffe), Belgium, has produced its first Good Manufacturing Practice (GMP)-grade commercial radiopharmaceutical doses and delivered them to the AIRC [1] hospital collaboration in Charleroi, Belgium.
TMS Brussels South is one of Europe's largest radiopharmaceutical production facilities, with nine GMP lines, clean rooms, a radiopharmacy, and two cyclotrons across a 2,800 square metre footprint.
Raphael Ortiz, Chief Executive Officer, Telix International, commented, "We are excited to launch Telix's commercial radiopharmacy capability in Europe and demonstrate our ability to meet the needs of patients and partners. Through our bench-to-bedside capabilities we can now provide GMP-grade products and radiolabelling services to customers in Europe and beyond. This is a further point of differentiation for Telix."
Dr. Ivan Duran Derijckere, AIRC, added, "Following the accreditation of TMS Brussels South, many more regions in Belgium will now have access to GMP-grade radiopharmaceuticals. I would like to thank Telix for its leadership and continued investment in innovative products and services for patients with cancer, which will have a direct positive impact on outcomes including quality of life."
Prof. Dr. Nadia Withofs, President of the Belgian Society of Nuclear Medicine (BELNUC) continued, "Belgium and the Wallonia region have a rich history in nuclear medicine, and we are thrilled to see this continue with Telix's pioneering facility in Brussels South becoming GMP operational. TMS Brussels South can now manufacture GMP-grade 'hot doses' that are ready for patients today. And beyond this, the impressive research, development and manufacturing scale-up capabilities mean that it will also serve as a vital hub for future production of clinically and commercially important isotopes and radiopharmaceuticals."
For more information or to order finished radiopharmaceuticals, active pharmaceutical ingredients, or related services, licensed healthcare professionals in Europe can visit: https://www.radiopharmastore.com/
About Telix Manufacturing Solutions (TMS)
TMS is a global network of facilities for in-house production and distribution of radiopharmaceuticals, including through collaboration with strategic partners. Located in the heart of Belgium's 'Radiopharma Valley', TMS Brussels South is one of Europe's largest radiopharmaceutical production facilities, with nine GMP lines, clean rooms, a radiopharmacy, and two cyclotrons across a 2,800 square metre footprint. TMS Brussels South also has extensive research and development (R&D) capabilities, with a focus on alpha-emitting isotopes.
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com
Legal Notices |
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. |
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. |
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. |
©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates - all rights reserved. Trademark registration status may vary from country to country. |
[1] L'Association Interhospitalière de la Région de Charleroi, an inter-hospital collaboration between three hospitals: Grand Hopital de Charleroi (GHdC), Clinique Notre-Dame de Grâce de Gosselies (CNDG) and HUmani. |
Logo - https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/telix-manufacturing-solutions-belgium-delivers-first-gmp-grade-commercial-doses-302490637.html
